Le Lézard
Classified in: Health, Science and technology
Subject: MAT

The Ketamine Healing Clinic of Los Angeles Offers the Advanced Fibromyalgia Treatment Protocol for Fibromyalgia Sufferers

LOS ANGELES, Feb. 24, 2021 /PRNewswire-PRWeb/ -- Dr. David Mahjoubi, a leading board-certified Anesthesiologist and founder of the Ketamine Healing Clinic of Los Angeles provides IV ketamine treatment therapy to treat many health issues such as Depression (including treatment-resistant), PTSD, Anxiety and the chronic pain that patients with fibromyalgia suffer from. Fibromyalgia often appears dissociated in symptoms, and many doctors tend to treat the "separate conditions" instead of treating the patient as a whole. Patients may suffer from pain in multiple areas of the body, chronic headaches, burning sensations in their hands, and cramps in their feet, all at the same time. Patients often suffer through their condition because treating one symptom is not helping with all of the others. There is no known cure for fibromyalgia, yet the Advanced Fibromyalgia Protocol offered at the Ketamine Healing Clinic of Los Angeles has proven to be effective in treating its multiple symptoms.

Dr. David Mahjoubi has many years of clinical experience with intravenous ketamine and has seen firsthand the benefits of ketamine for people experiencing the chronic pain associated with fibromyalgia. After a set of IV infusions, patients are prescribed a ketamine nasal spray + oral Naltrexone to help significantly reduce their symptoms. There has been an astonishing 85%-90% success rate in reducing pain and anxiety associated with fibromyalgia with the Advanced Fibromyalgia Protocol. Dr. Mahjoubi is one of only a handful of doctors in the country offering ketamine nasal spray as a supplementary, at-home treatment for chronic pain to help maintain and extend the benefits of IV ketamine treatments.

"I have successfully helped patients with fibromyalgia who have waited years for helpful treatment. Patients' pain levels are being dramatically reduced, and their quality of life is being handed back to them with our innovative treatment plan," says Dr. Mahjoubi.

More about Dr. David Mahjoubi:

David Mahjoubi, M.D. is a board-certified anesthesiologist. He earned his medical degree from The Chicago Medical School and completed his residency training in Anesthesiology at the University of Southern California (USC)/Los Angeles County Medical Center after completing an internship at the UCLA Medical Center. He is the author of multiple publications in the medical field. Dr. Mahjoubi has extensive experience administering IV ketamine dating back to 2006. He founded The Ketamine Healing Clinic of Los Angeles in 2014 after noticing the profound mental health benefits ketamine treatments can provide. If you are suffering from fibromyalgia, chronic pain, or a mood condition, visit the Ketamine Healing Clinic of Los Angeles' website at http://www.ketaminehealing.com, or contact the clinic at (866) 987-7874.

Media Contact

Dr. David Mahjoubi, Ketamine Healing Clinic of Los Angeles, (424) 278-4241, drdavidm@ketaminehealing.com


SOURCE Ketamine Healing Clinic of Los Angeles

These press releases may also interest you

at 07:45
The "Global Regenerative Medicines Market 2020-2030: Focus on Products, Applications, 17 Countries' Data and Competitive Landscape" report has been added to ResearchAndMarkets.com's offering. The global regenerative medicines market is projected to...

at 07:45
CalAmp® , a connected intelligence company that helps people and businesses work smarter, today unveiled its new SC1302tm single-use smart tracking device that can monitor temperatures as low as -20 degrees Celsius. The smart device provides granular...

at 07:41
January ? March Revenues amounted to MSEK 713.0 (793.6), corresponding to a decrease of -10% for the period.  Revenues amounted to MSEK 713.0 ( 793.6), corresponding to a decrease of -10% for the period. The organic growth* during the first quarter...

at 07:35
Organicell Regenerative Medicine, Inc. , a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug...

at 07:30
Lowell Farms , a leading, vertically-integrated California cannabis company, will report its financial results for the fiscal First Quarter (ended March 31, 2021) after market closes on May 4. Following the release, Lowell Farms will host an earnings...

at 07:30
HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has identified a second drug target for the treatment of gout under its collaboration with Horizon Therapeutics plc that was established in January 2019. Leveraging...

News published on 24 february 2021 at 12:00 and distributed by: